1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 Real-Time PCR (q-PCR) 1.2.3 Immunohistochemistry (IHC) 1.2.4 Next-Generation Sequencing (NGS) 1.2.5 Fluorescent In-Situ Hybridization (FISH) 1.3 Market by Application 1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Hospital-associated Labs 1.3.3 Cancer Research Institutes 1.3.4 Diagnostic Centers 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2018-2029) 2.2 Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region 2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2018-2023) 2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2024-2029) 2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics 2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends 2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers 2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges 2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue 3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2018-2023) 3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2018-2023) 3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue 3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio 3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022 3.5 Next-Generation Breast Cancer Diagnostic and Screening Key Players Head office and Area Served 3.6 Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service 3.7 Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type 4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2018-2023) 4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2024-2029) 5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application 5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2018-2023) 5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029) 6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) 6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029) 7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) 7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029) 8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) 8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029) 9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) 9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029) 10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) 10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Abbott Laboratories 11.1.1 Abbott Laboratories Company Detail 11.1.2 Abbott Laboratories Business Overview 11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.1.5 Abbott Laboratories Recent Development 11.2 Agendia 11.2.1 Agendia Company Detail 11.2.2 Agendia Business Overview 11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.2.5 Agendia Recent Development 11.3 Agilent Technologies 11.3.1 Agilent Technologies Company Detail 11.3.2 Agilent Technologies Business Overview 11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.3.5 Agilent Technologies Recent Development 11.4 Ambry Genetics 11.4.1 Ambry Genetics Company Detail 11.4.2 Ambry Genetics Business Overview 11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.4.5 Ambry Genetics Recent Development 11.5 Biocept 11.5.1 Biocept Company Detail 11.5.2 Biocept Business Overview 11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.5.5 Biocept Recent Development 11.6 Biotheranostics 11.6.1 Biotheranostics Company Detail 11.6.2 Biotheranostics Business Overview 11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.6.5 Biotheranostics Recent Development 11.7 Centogene 11.7.1 Centogene Company Detail 11.7.2 Centogene Business Overview 11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.7.5 Centogene Recent Development 11.8 Danaher Corporation 11.8.1 Danaher Corporation Company Detail 11.8.2 Danaher Corporation Business Overview 11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.8.5 Danaher Corporation Recent Development 11.9 EXACT Sciences Corporation 11.9.1 EXACT Sciences Corporation Company Detail 11.9.2 EXACT Sciences Corporation Business Overview 11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.9.5 EXACT Sciences Corporation Recent Development 11.10 Roche Holding AG 11.10.1 Roche Holding AG Company Detail 11.10.2 Roche Holding AG Business Overview 11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.10.5 Roche Holding AG Recent Development 11.11 Fulgent Genetics 11.11.1 Fulgent Genetics Company Detail 11.11.2 Fulgent Genetics Business Overview 11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.11.5 Fulgent Genetics Recent Development 11.12 Illumina 11.12.1 Illumina Company Detail 11.12.2 Illumina Business Overview 11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.12.5 Illumina Recent Development 11.13 Invitae 11.13.1 Invitae Company Detail 11.13.2 Invitae Business Overview 11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.13.5 Invitae Recent Development 11.14 Lucence Diagnostics Pte Ltd 11.14.1 Lucence Diagnostics Pte Ltd Company Detail 11.14.2 Lucence Diagnostics Pte Ltd Business Overview 11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.14.5 Lucence Diagnostics Pte Ltd Recent Development 11.15 Myriad Genetics 11.15.1 Myriad Genetics Company Detail 11.15.2 Myriad Genetics Business Overview 11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction 11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) 11.15.5 Myriad Genetics Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of Real-Time PCR (q-PCR) Table 3. Key Players of Immunohistochemistry (IHC) Table 4. Key Players of Next-Generation Sequencing (NGS) Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH) Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) & (US$ Million) Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2018-2023) Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2024-2029) Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2018-2023) & (US$ Million) Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2018-2023) Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2022) Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2022 Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2018-2023) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service Table 23. Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2018-2023) & (US$ Million) Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2018-2023) Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2024-2029) Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2018-2023) & (US$ Million) Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2018-2023) Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2024-2029) Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million) Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million) Table 36. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million) Table 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million) Table 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 40. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) & (US$ Million) Table 41. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2024-2029) & (US$ Million) Table 42. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million) Table 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 46. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million) Table 47. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million) Table 48. Abbott Laboratories Company Detail Table 49. Abbott Laboratories Business Overview Table 50. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product Table 51. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 52. Abbott Laboratories Recent Development Table 53. Agendia Company Detail Table 54. Agendia Business Overview Table 55. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product Table 56. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 57. Agendia Recent Development Table 58. Agilent Technologies Company Detail Table 59. Agilent Technologies Business Overview Table 60. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product Table 61. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 62. Agilent Technologies Recent Development Table 63. Ambry Genetics Company Detail Table 64. Ambry Genetics Business Overview Table 65. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Table 66. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 67. Ambry Genetics Recent Development Table 68. Biocept Company Detail Table 69. Biocept Business Overview Table 70. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product Table 71. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 72. Biocept Recent Development Table 73. Biotheranostics Company Detail Table 74. Biotheranostics Business Overview Table 75. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product Table 76. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 77. Biotheranostics Recent Development Table 78. Centogene Company Detail Table 79. Centogene Business Overview Table 80. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product Table 81. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 82. Centogene Recent Development Table 83. Danaher Corporation Company Detail Table 84. Danaher Corporation Business Overview Table 85. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Table 86. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 87. Danaher Corporation Recent Development Table 88. EXACT Sciences Corporation Company Detail Table 89. EXACT Sciences Corporation Business Overview Table 90. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Table 91. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 92. EXACT Sciences Corporation Recent Development Table 93. Roche Holding AG Company Detail Table 94. Roche Holding AG Business Overview Table 95. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product Table 96. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 97. Roche Holding AG Recent Development Table 98. Fulgent Genetics Company Detail Table 99. Fulgent Genetics Business Overview Table 100. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Table 101. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 102. Fulgent Genetics Recent Development Table 103. Illumina Company Detail Table 104. Illumina Business Overview Table 105. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product Table 106. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 107. Illumina Recent Development Table 108. Invitae Company Detail Table 109. Invitae Business Overview Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product Table 111. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 112. Invitae Recent Development Table 113. Lucence Diagnostics Pte Ltd Company Detail Table 114. Lucence Diagnostics Pte Ltd Business Overview Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product Table 116. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 117. Lucence Diagnostics Pte Ltd Recent Development Table 118. Myriad Genetics Company Detail Table 119. Myriad Genetics Business Overview Table 120. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Table 121. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million) Table 122. Myriad Genetics Recent Development Table 123. Research Programs/Design for This Report Table 124. Key Data Information from Secondary Sources Table 125. Key Data Information from Primary Sources List of Figures Figure 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2022 VS 2029 Figure 3. Real-Time PCR (q-PCR) Features Figure 4. Immunohistochemistry (IHC) Features Figure 5. Next-Generation Sequencing (NGS) Features Figure 6. Fluorescent In-Situ Hybridization (FISH) Features Figure 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2022 VS 2029 Figure 9. Hospital-associated Labs Case Studies Figure 10. Cancer Research Institutes Case Studies Figure 11. Diagnostic Centers Case Studies Figure 12. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2022 VS 2029 Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2022 Figure 17. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2022) Figure 18. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022 Figure 19. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029) Figure 21. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 22. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029) Figure 25. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2018-2029) Figure 33. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 38. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 40. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029) Figure 41. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029) Figure 45. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million) Figure 47. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 48. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 49. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 50. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 51. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 52. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 53. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 54. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 55. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 56. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 57. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 58. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 59. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 60. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 61. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) Figure 62. Bottom-up and Top-down Approaches for This Report Figure 63. Data Triangulation Figure 64. Key Executives Interviewed

Abbott Laboratories Agendia Agilent Technologies Ambry Genetics Biocept Biotheranostics Centogene Danaher Corporation EXACT Sciences Corporation Roche Holding AG Fulgent Genetics Illumina Invitae Lucence Diagnostics Pte Ltd Myriad Genetics